Cowen Maintains Positive View on Immunomedics (IMMU) Despite Form 483 Observations
Tweet Send to a Friend
Cowen analyst Phil Nadeau reiterated an Outperform rating and $30.00 price target on Immunomedics (NASDAQ: IMMU) after Form 483 observations ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
